How Many Epizyme, Inc. (NASDAQ:EPZM)’s Analysts Are Bullish?

Epizyme, Inc. (NASDAQ:EPZM) Logo
Investors sentiment increased to 2.34 in Q2 2019. Its up 0.60, from 1.74 in 2019Q1. It is positive, as 16 investors sold Epizyme, Inc. shares while 19 reduced holdings. 32 funds opened positions while 50 raised stakes. 80.53 million shares or 8.06% more from 74.53 million shares in 2019Q1 were reported.
Tekla Mngmt Llc reported 399,604 shares. Captrust Financial Advisors owns 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 747 shares. Charles Schwab Invest Management Inc holds 459,308 shares or 0% of its portfolio. Art Advsr Lc, New York-based fund reported 26,239 shares. Shell Asset Mgmt Com invested in 16,776 shares. Jefferies Limited invested in 40,200 shares. Morgan Stanley invested in 306,908 shares or 0% of the stock. First Light Asset Management Limited Liability Company holds 200,063 shares or 0.35% of its portfolio. Great West Life Assurance Can holds 0% or 11,099 shares. Voya Inv Ltd Liability Corporation has 279,362 shares. Hanseatic Service stated it has 203 shares. Goldman Sachs Grp Inc Incorporated accumulated 0% or 469,933 shares. Boothbay Fund Management Ltd Liability stated it has 47,474 shares. Moreover, Ghost Tree Lc has 1.22% invested in Epizyme, Inc. (NASDAQ:EPZM) for 465,000 shares. Fred Alger Incorporated owns 0% invested in Epizyme, Inc. (NASDAQ:EPZM) for 57,000 shares.

Epizyme, Inc. (NASDAQ:EPZM) Ratings Coverage

Among 2 analysts covering Epizyme (NASDAQ:EPZM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Epizyme has $25 highest and $18 lowest target. $21.50’s average target is 79.77% above currents $11.96 stock price. Epizyme had 3 analyst reports since June 1, 2019 according to SRatingsIntel. H.C. Wainwright maintained the stock with “Buy” rating in Monday, June 24 report. As per Friday, June 21, the company rating was maintained by Cowen & Co. Below is a list of Epizyme, Inc. (NASDAQ:EPZM) latest ratings and price target changes.

24/06/2019 Broker: H.C. Wainwright Rating: Buy New Target: $25 Maintain
21/06/2019 Broker: Cowen & Co Rating: Buy New Target: $18 Maintain
01/06/2019 Broker: BidaskScore Rating: Buy Upgrade

The stock decreased 1.48% or $0.18 during the last trading session, reaching $11.96. About 1.69M shares traded or 119.20% up from the average. Epizyme, Inc. (NASDAQ:EPZM) has risen 7.80% since September 13, 2018 and is uptrending. It has outperformed by 7.80% the S&P500.

Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States. The company has market cap of $1.09 billion. The Company’s product candidates include tazemetostat, an inhibitor of the EZH2 HMT, which is in five-arm Phase II clinical trial for patients with relapsed or refractory non-hodgkin lymphoma ; Phase II clinical trial for relapsed or refractory patients with mesothelioma; Phase I dose-escalation and expansion study for children with INI1-negative solid tumors; Phase II and Ib clinical trials for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL); Phase Ib/II clinical trial for elderly patients with DLBCL; and Phase II clinical trial for relapsed or refractory patients with mesothelioma characterized by BAP1 loss-of-function, as well as Phase II clinical trial in adult patients with ovarian cancer. It currently has negative earnings. The firm is also developing additional programs, such as pinometostat, an intravenously administered small molecule inhibitor of DOT1L for the treatment of acute leukemias; and PRMT5 inhibitor that is in Phase I clinical trial for patients with solid tumors and NHL.

More notable recent Epizyme, Inc. (NASDAQ:EPZM) news were published by: which released: “Where Will Epizyme Be in 1 Year? – Nasdaq” on September 05, 2019, also with their article: “Epizyme (EPZM) Focuses on Developing Lead Drug Tazemetostat – Nasdaq” published on August 15, 2019, published: “Epizyme A Buy On Firmer Tazemetostat Timeline – Seeking Alpha” on June 05, 2019. More interesting news about Epizyme, Inc. (NASDAQ:EPZM) were released by: and their article: “Epizyme beats Q1 consensus – Seeking Alpha” published on May 06, 2019 as well as‘s news article titled: “Epizyme closes $172M capital raise – Seeking Alpha” with publication date: March 12, 2019.

Epizyme, Inc. (NASDAQ:EPZM) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.